{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T07:48:54Z","timestamp":1775461734576,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-025-04841-1","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T05:44:48Z","timestamp":1764567888000},"page":"6939-6958","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serious adverse events reported with sodium-glucose cotransporter-2 (SGLT2) inhibitors in the FAERS database (2013\u20132024): a pharmacovigilance study"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2873-3287","authenticated-orcid":false,"given":"Marya","family":"Ahsan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"4841_CR1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/eurheartj\/ehab765","volume":"43","author":"E Braunwald","year":"2022","unstructured":"Braunwald E (2022) SGLT2 inhibitors: the statins of the 21st century. Eur Heart J 43:1029\u20131030. https:\/\/doi.org\/10.1093\/eurheartj\/ehab765","journal-title":"Eur Heart J"},{"key":"4841_CR2","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383:1425\u20131435. https:\/\/doi.org\/10.1056\/NEJMoa2004967","journal-title":"N Engl J Med"},{"key":"4841_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12933-019-0869-2","volume":"18","author":"S Carbone","year":"2019","unstructured":"Carbone S, Dixon DL (2019) The CANVAS program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 18:64. https:\/\/doi.org\/10.1186\/s12933-019-0869-2","journal-title":"Cardiovasc Diabetol"},{"key":"4841_CR4","unstructured":"Council for International Organizations of Medical Sciences (2010) Practical aspects of signal detection in pharamcovigilance: reportof CIOMS Working Group VIII. Geneve: CIOMS. https:\/\/cioms.ch\/wp-content\/uploads\/2018\/03\/WG8-Signal-Detection.pdf. Accessed 20 Oct 2025"},{"key":"4841_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7326\/M20-0289","volume":"173","author":"A Douros","year":"2020","unstructured":"Douros A, Lix LM, Fralick M et al (2020) Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis\u202f: a multicenter cohort study. Ann Intern Med 173:417\u2013425. https:\/\/doi.org\/10.7326\/M20-0289","journal-title":"Ann Intern Med"},{"key":"4841_CR6","unstructured":"European Medicines Agency (2025) MedDRA Important Medical Event Terms List (Version 28.0). EMA. Retrieved from https:\/\/www.ema.europa.eu\/en\/documents\/other\/meddra-important-medical-event-terms-list-version-28-0_en.xlsx.\u00a0Accessed 29 Sept 2025"},{"key":"4841_CR7","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","volume":"5","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Avogaro A (2017) SGLT2 inhibitors and amputations in the US FDA adverse event reporting system. Lancet Diabetes Endocrinol 5:680\u2013681. https:\/\/doi.org\/10.1016\/S2213-8587(17)30257-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4841_CR8","unstructured":"Food and Drug Administration (2020) 2020 FDA Guidance for Diabetes Drug Development: Cardiorenal Populations and Outcomes: Lessons Learned and Future Directions. In: American College of Cardiology. https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2021\/09\/10\/13\/46\/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fArticles%2f2021%2f09%2f10%2f13%2f46%2f2020-FDA-Guidance-for-Diabetes-Drug-Development. Accessed 23 Sept 2025"},{"key":"4841_CR9","unstructured":"Food and Drug Administration (2025) FDA Adverse Event Reporting System (FAERS) Public Dashboard. In: FDA. https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed 15 Nov 2025"},{"key":"4841_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/DMSO.S184437","volume":"12","author":"H Jakher","year":"2019","unstructured":"Jakher H, Chang TI, Tan M, Mahaffey KW (2019) Canagliflozin review \u2013 safety and efficacy profile in patients with T2DM. Diabetes Metab Syndr Obes 12:209\u2013215. https:\/\/doi.org\/10.2147\/DMSO.S184437","journal-title":"Diabetes Metab Syndr Obes"},{"key":"4841_CR11","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","volume":"28","author":"PS Jhund","year":"2022","unstructured":"Jhund PS, Kondo T, Butt JH et al (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med 28:1956\u20131964. https:\/\/doi.org\/10.1038\/s41591-022-01971-4","journal-title":"Nat Med"},{"key":"4841_CR12","doi-asserted-by":"publisher","first-page":"e62957","DOI":"10.7759\/cureus.62957","volume":"16","author":"Z Khakhar","year":"2024","unstructured":"Khakhar Z, Manji S, Patel RK, Ali SK (2024) Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors and the Risk of Pancreatitis: A Case Report. Cureus 16:e62957. https:\/\/doi.org\/10.7759\/cureus.62957","journal-title":"Cureus"},{"key":"4841_CR13","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/dom.13255","volume":"20","author":"C Khouri","year":"2018","unstructured":"Khouri C, Cracowski J-L, Roustit M (2018) SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect? Diabetes Obes Metab 20:1531\u20131534. https:\/\/doi.org\/10.1111\/dom.13255","journal-title":"Diabetes Obes Metab"},{"key":"4841_CR14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2022) KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 102:S1\u2013S127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"key":"4841_CR15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/dom.12825","volume":"19","author":"D Li","year":"2017","unstructured":"Li D, Wang T, Shen S et al (2017) Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 19:348\u2013355. https:\/\/doi.org\/10.1111\/dom.12825","journal-title":"Diabetes Obes Metab"},{"key":"4841_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40801-021-00277-0","volume":"9","author":"W Li","year":"2022","unstructured":"Li W, Katamreddy A, Kataria R et al (2022) Sodium-glucose cotransporter-2 inhibitor use is associated with a reduced risk of heart failure hospitalization in patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus: a real-world study on a diverse urban population. Drugs - Real World Outcomes 9:53\u201362. https:\/\/doi.org\/10.1007\/s40801-021-00277-0","journal-title":"Drugs - Real World Outcomes"},{"key":"4841_CR17","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1007\/s00125-019-4839-8","volume":"62","author":"DR Matthews","year":"2019","unstructured":"Matthews DR, Li Q, Perkovic V et al (2019) Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS program. Diabetologia 62:926\u2013938. https:\/\/doi.org\/10.1007\/s00125-019-4839-8","journal-title":"Diabetologia"},{"key":"4841_CR18","doi-asserted-by":"publisher","first-page":"18817","DOI":"10.1038\/s41598-023-46275-w","volume":"13","author":"D Montes-Grajales","year":"2023","unstructured":"Montes-Grajales D, Garcia-Serna R, Mestres J (2023) Impact of the COVID-19 pandemic on the spontaneous reporting and signal detection of adverse drug events. Sci Rep 13:18817. https:\/\/doi.org\/10.1038\/s41598-023-46275-w","journal-title":"Sci Rep"},{"key":"4841_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/metabo14050264","volume":"14","author":"C Morace","year":"2024","unstructured":"Morace C, Lorello G, Bellone F et al (2024) Ketoacidosis and SGLT2 inhibitors: a narrative review. Metabolites 14:264. https:\/\/doi.org\/10.3390\/metabo14050264","journal-title":"Metabolites"},{"key":"4841_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12123958","volume":"12","author":"A Nani","year":"2023","unstructured":"Nani A, Carrara F, Paulesu CME et al (2023) Association of sodium-glucose cotransporter 2 inhibitors with osteomyelitis and other lower limb safety outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials. J Clin Med 12:3958. https:\/\/doi.org\/10.3390\/jcm12123958","journal-title":"J Clin Med"},{"key":"4841_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.009837","volume":"16","author":"ME Nassif","year":"2023","unstructured":"Nassif ME, Windsor SL, Gosch K et al (2023) Dapagliflozin improves heart failure symptoms and physical limitations across the full range of ejection fraction: pooled patient-level analysis from DEFINE-HF and PRESERVED-HF trials. Circ Heart Fail 16:e009837. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.122.009837","journal-title":"Circ Heart Fail"},{"key":"4841_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdi.12401","volume":"7","author":"W Ogawa","year":"2016","unstructured":"Ogawa W, Sakaguchi K (2016) Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig 7:135\u2013138. https:\/\/doi.org\/10.1111\/jdi.12401","journal-title":"J Diabetes Investig"},{"key":"4841_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.17925\/EE.2014.10.02.117","volume":"10","author":"RA Oliveros","year":"2014","unstructured":"Oliveros RA, Pham SV, Bailey SR, Chilton RJ (2014) Glucose Control and Cardiovascular Outcomes in Clinical Trials of Sodium Glucose Co-transporter 2 Inhibitor Treatments in Type 2 Diabetes. Eur Endocrinol 10:117\u2013123. https:\/\/doi.org\/10.17925\/EE.2014.10.02.117","journal-title":"Eur Endocrinol"},{"key":"4841_CR24","unstructured":"Padda IS, Mahtani AU, Parmar M (2025) Sodium-Glucose Transport 2 (SGLT2) Inhibitors. In: StatPearls. StatPearls Publishing, Treasure Island (FL). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576405\/. Accessed 14 Oct 2025"},{"key":"4841_CR25","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s11096-022-01476-7","volume":"44","author":"H Palapra","year":"2022","unstructured":"Palapra H, Viswam SK, Kalaiselvan V, Undela K (2022) SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports. Int J Clin Pharm 44:1425\u20131433. https:\/\/doi.org\/10.1007\/s11096-022-01476-7","journal-title":"Int J Clin Pharm"},{"key":"4841_CR26","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2337\/dc15-0843","volume":"38","author":"AL Peters","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB et al (2015) Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38:1687\u20131693. https:\/\/doi.org\/10.2337\/dc15-0843","journal-title":"Diabetes Care"},{"key":"4841_CR27","unstructured":"Posit team (2025) RStudio: Integrated Development Environment for R. Posit Software, PBC, Boston, MA.\u00a0http:\/\/www.posit.co\/. Accessed 23 Sept 2025"},{"key":"4841_CR28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","volume":"55","author":"R Puckrin","year":"2018","unstructured":"Puckrin R, Saltiel M-P, Reynier P et al (2018) SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 55:503\u2013514. https:\/\/doi.org\/10.1007\/s00592-018-1116-0","journal-title":"Acta Diabetol"},{"key":"4841_CR29","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","volume":"61","author":"T Rieg","year":"2018","unstructured":"Rieg T, Vallon V (2018) Development of SGLT1 and SGLT2 inhibitors. Diabetologia 61:2079\u20132086. https:\/\/doi.org\/10.1007\/s00125-018-4654-7","journal-title":"Diabetologia"},{"key":"4841_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2213-8587(23)00009-8","volume":"11","author":"M Schechter","year":"2023","unstructured":"Schechter M, Wiviott SD, Raz I et al (2023) Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. Lancet Diabetes Endocrinol 11:233\u2013241. https:\/\/doi.org\/10.1016\/S2213-8587(23)00009-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4841_CR31","doi-asserted-by":"publisher","first-page":"204209862311813","DOI":"10.1177\/20420986231181334","volume":"14","author":"BA Stottlemyer","year":"2023","unstructured":"Stottlemyer BA, McDermott MC, Minogue MR et al (2023) Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study. Ther Adv Drug Saf 14:20420986231181336. https:\/\/doi.org\/10.1177\/20420986231181334","journal-title":"Ther Adv Drug Saf"},{"key":"4841_CR32","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/EDE.0b013e3181577511","volume":"18","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG et al (2007) Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology 18:805\u2013835. https:\/\/doi.org\/10.1097\/EDE.0b013e3181577511","journal-title":"Epidemiology"},{"key":"4841_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","volume":"101","author":"NB Watts","year":"2016","unstructured":"Watts NB, Bilezikian JP, Usiskin K et al (2016) Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 101:157\u2013166. https:\/\/doi.org\/10.1210\/jc.2015-3167","journal-title":"J Clin Endocrinol Metab"},{"key":"4841_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"4841_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1145587","author":"S Yang","year":"2023","unstructured":"Yang S, Liu Y, Zhang S et al (2023) Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1145587","journal-title":"Front Pharmacol"},{"key":"4841_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.977582","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang L, Mao W, Li X et al (2022) Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: based on food and drug administration adverse event report system database. Front Pharmacol 13:977582. https:\/\/doi.org\/10.3389\/fphar.2022.977582","journal-title":"Front Pharmacol"},{"key":"4841_CR37","doi-asserted-by":"publisher","first-page":"1110575","DOI":"10.3389\/fphar.2023.1110575","volume":"14","author":"H Zhao","year":"2023","unstructured":"Zhao H, Li Z-R, Zhang Q et al (2023) Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: a pharmacovigilance study of the FAERS database. Front Pharmacol 14:1110575. https:\/\/doi.org\/10.3389\/fphar.2023.1110575","journal-title":"Front Pharmacol"},{"key":"4841_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.766125","volume":"12","author":"X Zhou","year":"2021","unstructured":"Zhou X, Ye X, Guo X et al (2021) Safety of SGLT2 inhibitors: a pharmacovigilance study from 2013 to 2021 based on FAERS. Front Pharmacol 12:766125. https:\/\/doi.org\/10.3389\/fphar.2021.766125","journal-title":"Front Pharmacol"},{"key":"4841_CR39","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04841-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04841-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04841-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:51:34Z","timestamp":1775458294000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04841-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4841"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04841-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational study based on publicly available datasets. The Institutional Review Board has confirmed that no ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}